Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Jizheng Tian"'
Autor:
Hongchao Zhen, Jizheng Tian, Guangxin Li, Pengfei Zhao, Ying Zhang, Juanjuan Che, Bangwei Cao
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-15 (2023)
Abstract Background Anlotinib is a multi-targeted receptor tyrosine kinase inhibitor (TKI) which has exhibited encouraging clinical activity in advanced non-small cell lung cancer (NSCLC) and soft tissue sarcoma. Raltitrexed is well known to be effec
Externí odkaz:
https://doaj.org/article/9d0368a2210b4ababf2c4d8cbe0aad45
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundSmall cell lung cancer (SCLC) constitutes 15% of all lung cancer cases, with a comparatively low survival rate. The advent of immune checkpoint inhibitors (ICIs) has provided new alternatives for treating SCLC. However, the effectiveness of
Externí odkaz:
https://doaj.org/article/f0a2d6aebd824354b8702fa98bd51b35
Publikováno v:
International journal of clinical practice. 2022
Statins are suggested to improve cancer survival by possible anti-inflammatory effect. However, it remains unclear if concomitant use of statins could improve the efficacy of immune checkpoint inhibitors (ICIs) in patients with non-small-cell lung ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d1e472a87e4f306a8710507026359f1
https://pubmed.ncbi.nlm.nih.gov/35855055
https://pubmed.ncbi.nlm.nih.gov/35855055